Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
40 studies found for:    "Paroxysmal nocturnal hemoglobinuria"
Show Display Options
Download search resultsDownload the search results for:
"Paroxysmal nocturnal hemoglobinuria" (40 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Condition: Paroxysmal Nocturnal Hemoglobinuria
Intervention:
2 Completed Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
Conditions: Paroxysmal Nocturnal Hemoglobinuria;   PNH
Intervention:
3 Completed Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease
Conditions: Rheologic Disease;   Sickle Cell Disease;   Paroxysmal Nocturnal Hemoglobinuria
Intervention: Other: Imaging
4 Active, not recruiting Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria
Conditions: Paroxysmal Nocturnal Hemoglobinuria;   Hemoglobinuria;   Hemoglobinuria, Paroxysmal;   Proteinuria;   Urination Disorders;   Thrombosis;   Bone Marrow Failure;   Aplastic Anemia,;   Anemia, Hemolytic
Interventions: Drug: Levamisole+cyclosporin A+Glucocorticoids;   Drug: cyclosporin A+Glucocorticoids;   Drug: Glucocorticoids
5 Completed C07-001: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
Condition: Paroxysmal Nocturnal Hemoglobinuria
Intervention: Drug: Eculizumab
6 Completed E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
Condition: Paroxysmal Nocturnal Hemoglobinuria
Intervention: Drug: Eculizumab
7 Active, not recruiting Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)
Conditions: Paroxysmal Nocturnal Hemoglobinuria;   Hemoglobinuria;   Hemoglobinuria, Paroxysmal;   Proteinuria;   Urination Disorders;   Thrombosis;   Bone Marrow Failure;   Aplastic Anemia,;   Anemia, Hemolytic
Interventions: Drug: Levamisole+cyclosporin A+Glucocorticoids;   Drug: cyclosporin A+Glucocorticoids;   Drug: Glucocorticoids
8 Completed Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria
Condition: Paroxysmal Hemoglobinuria
Intervention:
9 Terminated Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: Drug: ALXN1102;   Drug: ALXN1103
10 Completed Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
Condition: Paroxysmal Hemoglobinuria, Nocturnal
Intervention: Drug: Eculizumab
11 Unknown  Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Conditions: Aplastic Anemia;   Paroxysmal Hemoglobinuria, Nocturnal
Interventions: Drug: cyclophosphamide;   Drug: filgrastim
12 Unknown  Study of Global Coagulation Tests in Patients With Paroxysmal Nocturnal Haemoglobinuria
Condition: Paroxysmal Nocturnal Haemoglobinuria
Intervention:
13 Completed Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Paroxysmal Hemoglobinuria, Nocturnal
Intervention: Drug: eculizumab
14 Not yet recruiting A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention: Drug: APL-2
15 Recruiting Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
Intervention: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
16 Completed Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
Conditions: Allogeneic Stem Cell Transplant;   Leukemia;   Non-Hodgkins;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome;   Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention: Drug: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
17 Completed The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Hemoglobinuria, Paroxysmal
Intervention:
18 Completed Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
Condition: Hemoglobinuria, Paroxysmal
Intervention: Drug: Eculizumab
19 Recruiting Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Aplastic Anemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Paroxysmal Nocturnal Hemoglobinuria;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Severe Combined Immunodeficiency;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
20 Completed Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies
Conditions: Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Paroxysmal Nocturnal Hemoglobinuria;   Hodgkin's Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Drug: Systematic chemotherapy and antibodies;   Procedure: Allogeneic stem cell transplantation;   Device: Miltenyi CliniMACS

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years